NYSE:HIMSHealthcare
Hims & Hers Health (HIMS) Is Down 12.9% After Halting Compounded Semaglutide Pill Amid FDA Scrutiny
In early February 2026, Hims & Hers Health launched and then quickly halted access to a low-cost compounded semaglutide weight loss pill after intense regulatory scrutiny, an FDA crackdown on compounded GLP-1 drugs, and a patent infringement lawsuit from Novo Nordisk.
This brief product rollout and reversal has spotlighted legal, regulatory, and safety questions around Hims & Hers’ broader GLP-1 offering and its model of marketing compounded medications at sharply lower prices than branded...